| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
EGFR/PARP-1-IN-1 (0.01-100 μM; 48 h) effectively inhibited the viability of MDA-MB-231 cells, with an IC50 value of 1.27 μM, and its selectivity for cancer cells was much higher than that for normal breast epithelial cells [1]. EGFR/PARP-1-IN-1 (1.27 μM; 48 h) increased apoptosis in MDA-MB-231 cells by 7.16 times and necrosis by 4.9 times [1]. EGFR/PARP-1-IN-1 (1.27 μM; 48 h) induced cell cycle arrest in MDA-MB-231 cells at the G2 phase and increased the proportion of cells in the sub-G1 phase, indicating that DNA damage and apoptosis exist in MDA-MB-231 cells [1]. EGFR/PARP-1-IN-1 (1.27 μM; 48 h) upregulates pro-apoptotic genes and downregulates anti-apoptotic gene Bcl-2, mainly through the intrinsic apoptosis pathway in MDA-MB-231 cells [1].
|
|---|---|
| Cell Assay |
Apoptosis analysis [1]
Cell Types: MDA-MB-231 triple-negative breast cancer cells Tested Concentrations: 1.27 μM Incubation Duration: 48 hours Experimental Results: Compared with untreated control cells (total apoptosis 1.83%, necrosis 1.78%), the total apoptotic cell death rate increased to 13.1% and the necrotic cell death rate increased to 8.74%, representing an increase of 7.16 times in apoptosis and 4.9 times in necrosis, respectively. Cell cycle analysis [1] Cell Types: MDA-MB-231 triple-negative breast cancer cells Tested Concentrations: 1.27 μM Incubation Duration: 48 hours Experimental Results: Compared with untreated control cells (G1 phase 44.41%, S phase 27.39%, G2 phase 26.48%, Sub-G1 phase 0.47%), G1 phase decreased to 33.06%, S phase decreased to 18.76%, G2 phase increased to 31.48%, and Sub-G1 phase increased to 11.37%. RT-PCR[1] Cell Types: MDA-MB-231 triple-negative breast cancer cells Tested Concentrations: 1.27 μM Incubation Duration: 48 hours Experimental Results: Increased expression of pro-apoptotic genes: P53 (9.87-fold), Bax (4.69-fold), Caspase-3 (5.66-fold), Caspase-8 (1.2-fold), and Caspase-9 (7.69-fold). Decreased expression of the anti-apoptotic gene Bcl-2 by 0.24-fold. |
| References |
| Molecular Formula |
C23H14BRF2N7O2
|
|---|---|
| Molecular Weight |
538.30
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
O=C(N/N=C1C(N(CC2=CN(C3=CC=C(F)C(F)=C3)N=N2)C4=C\1C=C(Br)C=C4)=O)C5=CC=NC=C5
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8577 mL | 9.2885 mL | 18.5770 mL | |
| 5 mM | 0.3715 mL | 1.8577 mL | 3.7154 mL | |
| 10 mM | 0.1858 mL | 0.9289 mL | 1.8577 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
